ConductScience.org, home

Paper2647

Multiple sedimenting species of properdin in human serum and interaction of purified properdin with the third component of complement.

Chapitis J and 1 other. J Exp Med, 1976. Cited by 40 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Multiple sedimenting species of properdin in human serum and interaction of purified properdin with the third component of complement. Papers, record 2647. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2647

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Multiple sedimenting species of properdin in human serum and interaction of purified properdin with the third component of complement.
PubMed
Journal
J Exp Med
PubMed
Year
1976
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
40
iCite
Relative citation ratio, by iCite
0.88
iCite
Revised in PubMed
2019-05-08
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chapitis JJ
2Lepow IHI H

Source PubMed

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Complement C3Major topic
Complement System ProteinsMajor topic
ProperdinMajor topic
ABO Blood-Group System
Humans
Hydrogen-Ion Concentration
Lipodystrophy
Temperature
Ultracentrifugation

Source PubMed

References29

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
11,165,475Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor.J Exp Med1975https://conductscience.org/library/papers/1165475PubMed
26,019,133Formation and functional significance of a molecular complex derived from the second and the fourth component of human complement.J Exp Med1967https://conductscience.org/library/papers/6019133PubMed
3123,262Changes in the immunochemical properties of highly purified properdin in human serum.J Immunol1975https://conductscience.org/library/papers/123262PubMed
413,713,200High specific activity iodination of gamma-globulin with iodine-131 monochloride.Cancer Res1960https://conductscience.org/library/papers/13713200PubMed
513,767,412A method for determining the sedimentation behavior of enzymes: application to protein mixtures.J Biol Chem1961https://conductscience.org/library/papers/13767412PubMed
614,151,101THE MACROMOLECULAR NATURE OF THE FIRST COMPONENT OF HUMAN COMPLEMENT.J Exp Med1964https://conductscience.org/library/papers/14151101PubMed
714,316,946ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT.J Exp Med1965https://conductscience.org/library/papers/14316946PubMed
814,415,902The properdin system and immunity. X. Characterization of partially purified human properdin.J Immunol1959https://conductscience.org/library/papers/14415902PubMed
104,117,597Homozygous deficiency of C3 in a patient with repeated infections.Lancet1972https://conductscience.org/library/papers/4117597PubMed
114,165,629Studies on the mode of action of the fifth, sixth and seventh component of human complement in immune haemolysis.Immunology1967https://conductscience.org/library/papers/4165629PubMed
124,166,243Immune hemolysis: a simplified method for the preparation of EAC'4 with guinea pig or with human complement.J Immunol1967https://conductscience.org/library/papers/4166243PubMed
134,169,693Properties of highly purified human properdin.J Immunol1968https://conductscience.org/library/papers/4169693PubMed
144,213,402Studies of complement complex C5b,6 eluted from--EAC-6: reaction of C5b,6 with EAC4b,3b and evidence on the role of C2a and C3b in the activation of C5.J Immunol1974https://conductscience.org/library/papers/4213402PubMed
154,477,550Studies on the sub-unit structure of human properdin.Immunochemistry1974https://conductscience.org/library/papers/4477550PubMed
164,555,693Observations on the effects of a proteinase from Serratia marcescens on the third component of human complement.Am J Med Sci1972https://conductscience.org/library/papers/4555693PubMed
174,719,679The membrane attack mechanism of complement. Verification of a stable C5-9 complex in free solution.J Exp Med1973https://conductscience.org/library/papers/4719679PubMed
184,737,061The membrane attack mechanism of complement. Reversible interactions among the five native components in free solution.J Exp Med1973https://conductscience.org/library/papers/4737061PubMed
194,738,906Solid phase radioimmunoassay of properdin.Immunochemistry1973https://conductscience.org/library/papers/4738906PubMed
2047,885The membrane attack mechanism of complement. Isolation and subunit composition of the C5b-9 complex.J Exp Med1975https://conductscience.org/library/papers/47885PubMed
214,831,630Computer stimulation of sedimentation in the ultracentrifuge. VII. Solutes undergoing indefinite self-association.Arch Biochem Biophys1974https://conductscience.org/library/papers/4831630PubMed

See all 29 references

Cited by17

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 40 citations.

PMIDTitleJournalYearIn PapersSource
32,485,958A New Era in Endothelial Injury Syndromes: Toxicity of CAR-T Cells and the Role of Immunity.Int J Mol Sci2020https://conductscience.org/library/papers/32485958PubMed
32,310,222Complementopathies and precision medicine.J Clin Invest2020https://conductscience.org/library/papers/32310222PubMed
29,167,939The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?Semin Immunopathol2018https://conductscience.org/library/papers/29167939PubMed
26,043,382Complement: an overview for the clinician.Hematol Oncol Clin North Am2015https://conductscience.org/library/papers/26043382PubMed
8,288,944Properdin: approaching four decades of research.Immunol Res1993https://conductscience.org/library/papers/8288944PubMed
6,696,726Mapping of the properdin-binding site in the third component of complement.Biochem J1984https://conductscience.org/library/papers/6696726PubMed
6,418,767Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.J Clin Invest1984https://conductscience.org/library/papers/6418767PubMed
3,421,908Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.Biochem J1988https://conductscience.org/library/papers/3421908PubMed
3,307,764Resolution and analysis of 'native' and 'activated' properdin.Biochem J1987https://conductscience.org/library/papers/3307764PubMed
3,140,783Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement.Biochem J1988https://conductscience.org/library/papers/3140783PubMed
1,067,618Control of the amplification convertase of complement by the plasma protein beta1H.Proc Natl Acad Sci U S A1976https://conductscience.org/library/papers/1067618PubMed
978,134Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.J Exp Med1976https://conductscience.org/library/papers/978134PubMed
871,825Cryoglobulinaemia in Henoch-Schönlein purpura.Br Med J1977https://conductscience.org/library/papers/871825PubMed
830,792Requirements for the solubilization of immune aggregates by complement: assembly of a factor B-dependent C3-convertase on the immune complexes.J Exp Med1977https://conductscience.org/library/papers/830792PubMed
670,397Requirements for the solubilization of immune aggregates by complement. The role of the classical pathway.J Clin Invest1978https://conductscience.org/library/papers/670397PubMed
559,720Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins.J Exp Med1977https://conductscience.org/library/papers/559720PubMed
273,923Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway.Proc Natl Acad Sci U S A1978https://conductscience.org/library/papers/273923PubMed

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
C3718PubTator's text mininghttps://conductscience.org/library/genes/718NCBI Gene
CFP5,199PubTator's text mininghttps://conductscience.org/library/genes/5199NCBI Gene
ERVK-3100,862,689PubTator's text mininghttps://conductscience.org/library/genes/100862689NCBI Gene

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2647

GET https://conductscience.org/api/papers/v1/2647/references?page=2